vs
Side-by-side financial comparison of Andersons, Inc. (ANDE) and Axsome Therapeutics, Inc. (AXSM). Click either name above to swap in a different company.
Andersons, Inc. is the larger business by last-quarter revenue ($329.5M vs $191.2M, roughly 1.7× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs -2.4%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs -1.8%).
The Andersons, Inc. is an American agribusiness established in 1947, that began as Andersons Truck Terminal (ATT) in the 1940s for the grain industry, headquartered in Maumee, Ohio. It is a diversified company rooted in agriculture that conducts business in the commodity merchandising, renewables, and plant nutrient sectors.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
ANDE vs AXSM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $329.5M | $191.2M |
| Net Profit | $67.4M | — |
| Gross Margin | 70.3% | — |
| Operating Margin | 26.6% | -33.1% |
| Net Margin | 20.5% | — |
| Revenue YoY | -2.4% | 57.4% |
| Net Profit YoY | 49.6% | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $191.2M | ||
| Q4 25 | $329.5M | $196.0M | ||
| Q3 25 | $295.8M | $171.0M | ||
| Q2 25 | $535.0M | $150.0M | ||
| Q1 25 | $370.8M | $121.5M | ||
| Q4 24 | $337.5M | $118.8M | ||
| Q3 24 | $231.9M | $104.8M | ||
| Q2 24 | $492.5M | $87.2M |
| Q1 26 | — | — | ||
| Q4 25 | $67.4M | $-28.6M | ||
| Q3 25 | $20.1M | $-47.2M | ||
| Q2 25 | $7.9M | $-48.0M | ||
| Q1 25 | $284.0K | $-59.4M | ||
| Q4 24 | $45.1M | $-74.9M | ||
| Q3 24 | $27.4M | $-64.6M | ||
| Q2 24 | $36.0M | $-79.3M |
| Q1 26 | — | — | ||
| Q4 25 | 70.3% | — | ||
| Q3 25 | 57.8% | — | ||
| Q2 25 | 29.6% | — | ||
| Q1 25 | 41.2% | — | ||
| Q4 24 | 63.1% | — | ||
| Q3 24 | 76.4% | — | ||
| Q2 24 | 35.6% | — |
| Q1 26 | — | -33.1% | ||
| Q4 25 | 26.6% | -13.8% | ||
| Q3 25 | 8.7% | -27.0% | ||
| Q2 25 | 4.6% | -24.5% | ||
| Q1 25 | 0.9% | -46.9% | ||
| Q4 24 | 19.9% | -61.1% | ||
| Q3 24 | 26.8% | -59.8% | ||
| Q2 24 | 11.6% | -89.5% |
| Q1 26 | — | — | ||
| Q4 25 | 20.5% | -14.6% | ||
| Q3 25 | 6.8% | -27.6% | ||
| Q2 25 | 1.5% | -32.0% | ||
| Q1 25 | 0.1% | -48.9% | ||
| Q4 24 | 13.4% | -63.1% | ||
| Q3 24 | 11.8% | -61.7% | ||
| Q2 24 | 7.3% | -91.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | $-0.55 | ||
| Q3 25 | $0.59 | $-0.94 | ||
| Q2 25 | $0.23 | $-0.97 | ||
| Q1 25 | $0.01 | $-1.22 | ||
| Q4 24 | $1.31 | $-1.54 | ||
| Q3 24 | $0.80 | $-1.34 | ||
| Q2 24 | $1.05 | $-1.67 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $98.3M | $305.1M |
| Total DebtLower is stronger | $560.0M | $70.0M |
| Stockholders' EquityBook value | $1.2B | — |
| Total Assets | $3.7B | $713.6M |
| Debt / EquityLower = less leverage | 0.45× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $305.1M | ||
| Q4 25 | $98.3M | $322.9M | ||
| Q3 25 | — | $325.3M | ||
| Q2 25 | — | $303.0M | ||
| Q1 25 | — | $300.9M | ||
| Q4 24 | $561.8M | $315.4M | ||
| Q3 24 | — | $327.3M | ||
| Q2 24 | — | $315.7M |
| Q1 26 | — | $70.0M | ||
| Q4 25 | $560.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $608.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | $88.3M | ||
| Q3 25 | $1.2B | $73.7M | ||
| Q2 25 | $1.4B | $73.1M | ||
| Q1 25 | $1.4B | $53.2M | ||
| Q4 24 | $1.4B | $57.0M | ||
| Q3 24 | $1.3B | $92.9M | ||
| Q2 24 | $1.3B | $102.9M |
| Q1 26 | — | $713.6M | ||
| Q4 25 | $3.7B | $689.8M | ||
| Q3 25 | $3.3B | $669.3M | ||
| Q2 25 | $3.4B | $639.8M | ||
| Q1 25 | $3.8B | $596.7M | ||
| Q4 24 | $4.1B | $568.5M | ||
| Q3 24 | $3.4B | $561.5M | ||
| Q2 24 | $3.3B | $548.2M |
| Q1 26 | — | — | ||
| Q4 25 | 0.45× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.2M | — |
| Free Cash FlowOCF − Capex | $-77.1M | — |
| FCF MarginFCF / Revenue | -23.4% | — |
| Capex IntensityCapex / Revenue | 21.5% | — |
| Cash ConversionOCF / Net Profit | -0.09× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-56.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-6.2M | $-18.7M | ||
| Q3 25 | $233.9M | $1.0M | ||
| Q2 25 | $299.3M | $-32.4M | ||
| Q1 25 | $-350.0M | $-43.4M | ||
| Q4 24 | $268.8M | $-26.2M | ||
| Q3 24 | $-2.1M | $-18.6M | ||
| Q2 24 | $304.4M | $-30.1M |
| Q1 26 | — | — | ||
| Q4 25 | $-77.1M | $-18.7M | ||
| Q3 25 | $167.0M | $988.0K | ||
| Q2 25 | $250.5M | $-32.4M | ||
| Q1 25 | $-396.6M | $-43.7M | ||
| Q4 24 | $212.9M | $-26.2M | ||
| Q3 24 | $-40.0M | $-18.7M | ||
| Q2 24 | $275.8M | $-30.2M |
| Q1 26 | — | — | ||
| Q4 25 | -23.4% | -9.6% | ||
| Q3 25 | 56.5% | 0.6% | ||
| Q2 25 | 46.8% | -21.6% | ||
| Q1 25 | -106.9% | -36.0% | ||
| Q4 24 | 63.1% | -22.1% | ||
| Q3 24 | -17.2% | -17.9% | ||
| Q2 24 | 56.0% | -34.6% |
| Q1 26 | — | — | ||
| Q4 25 | 21.5% | 0.0% | ||
| Q3 25 | 22.6% | 0.0% | ||
| Q2 25 | 9.1% | 0.0% | ||
| Q1 25 | 12.6% | 0.3% | ||
| Q4 24 | 16.6% | 0.0% | ||
| Q3 24 | 16.3% | 0.1% | ||
| Q2 24 | 5.8% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | -0.09× | — | ||
| Q3 25 | 11.61× | — | ||
| Q2 25 | 38.10× | — | ||
| Q1 25 | -1232.46× | — | ||
| Q4 24 | 5.96× | — | ||
| Q3 24 | -0.08× | — | ||
| Q2 24 | 8.46× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANDE
| Specialty And Primary Nutrients | $137.1M | 42% |
| Premium Ingredients | $66.1M | 20% |
| Segment Reporting Reconciling Item Other | $63.2M | 19% |
| Other | $63.1M | 19% |
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
